Stock comparison
Amneal Pharmaceuticals
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMRX
Amneal Pharmaceuticals
Market cap
$3.96B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMRX | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 72B | RMD |
| Benjamin Graham | 57D | 75B | RMD |
| Philip Fisher | 63C | 75B | RMD |
| Peter Lynch | 54C | 58C | RMD |
| Joel Greenblatt | 31F | 47D | RMD |
| Charlie Munger | 53D | 69B | RMD |
| Terry Smith | 42D | 73B | RMD |
Side-by-side metrics
| Metric | AMRX | RMD |
|---|---|---|
| Market cap | $3.96B | $30.18B |
| P/E (TTM) | 32.1x | 19.6x |
| EV/EBIT | 14.9x | 17.1x |
| ROIC (TTM) | 12.64% | 19.63% |
| Gross margin | 38.66% | 61.69% |
| Net margin | 4.02% | 27.44% |
| Revenue CAGR 5y | 9.58% | 12.64% |
| EPS CAGR 5y | 34.63% | 30.73% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMRX leads on
- Debt / Equity-vs 0.1x+100%
- EV/EBIT14.9xvs 17.1x+13%
- EPS CAGR 5y34.63%vs 30.73%+11%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $3.96B+87%
- Net margin27.44%vs 4.02%+85%
- P/E (TTM)19.6xvs 32.1x+39%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.